Marker Therapeutics
MRKR
43 hedge funds and large institutions have $86.4M invested in Marker Therapeutics in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 8 closing their positions.
1,483% more call options, than puts
Call options by funds: $190K | Put options by funds: $12K
624% more capital invested
Capital invested by funds: $11.9M → $86.4M (+$74.5M)
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
39% more funds holding
Funds holding: 31 → 43 (+12)
24% more ownership
Funds ownership: 10.34% → 34.33% (+24%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$36.4M |
| 2 |
PA
Perceptive Advisors
New York
|
+$14.6M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$10.9M |
| 4 |
AC
Armistice Capital
New York
|
+$10.8M |
| 5 |
6CM
683 Capital Management
New York
|
+$9.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.26M |
| 2 |
RI
RTW Investments
New York
|
-$1.9M |
| 3 |
MA
MYDA Advisors
Woodmere,
New York
|
-$424K |
| 4 |
Millennium Management
New York
|
-$315K |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$206K |
MRKR Hedge Fund Activity: Q4 2018 in Review
43 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2018, worth a combined $86.4M — up 624% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MRKR positions and 8 closed out — a net gain of 13 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $36.4M. The largest seller was CVI Holdings, exiting entirely with an estimated $2.26M sold.
- 43 institutional investors held Marker Therapeutics (MRKR) as of Q4 2018, up from 31 in Q3 2018.
- Funds reported $86.4M of Marker Therapeutics stock for Q4 2018, up 624% quarter-over-quarter.
- 21 funds opened new Marker Therapeutics positions in Q4 2018 and 8 closed out, a net change of +13 holders.
- The largest Marker Therapeutics buyer in Q4 2018 was NEA Management Company, an estimated $36.4M added.
- The largest Marker Therapeutics seller in Q4 2018 was CVI Holdings, an estimated $2.26M sold.
Based on aggregated 13F filings for Q4 2018.